Exelixis Inc. (EXEL)
Market Closed
16 Oct, 08:00 PM
$
62. 23
-0.6
-0.955%
$
15.64B Market Cap
80.72 P/E Ratio
- Div Yield
2.64M Volume
0.61 Eps
$ 62.83
Previous Close 
Want to track EXEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago.
Zacks | 2 years ago
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks | 2 years ago
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks | 2 years ago
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Zacks | 2 years ago
2026 © Marketlog. All Rights Reserved.
